Benzinga | Nov 17, 2020 08:30AM EST

BioMarin And Deep Genomics To Collaborate On Advancing Programs Identified Using Artificial Intelligence; Collaboration Will Use Genomics' AI Workbench To 'identify oligonucleotide drug candidates in four rare disease indications with high unmet need'

SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones as a part of the collaboration. BioMarin will receive an exclusive option to obtain Deep Genomics' rights to each program for development and commercialization. The companies did not disclose financial terms.